Historic milestone at Port of Los Angeles signals new era for renewable energy
Eco Wave Power (WAVE), a global leader in onshore wave energy technology, has officially launched its first U.S. wave energy project at the Port of Los Angeles, marking a historic moment for America’s clean energy transition. Developed in partnership with AltaSea and Shell Marine Renewable Energy (MRE), the installation represents the first onshore wave energy system in the United States and positions Eco Wave Power at the forefront of this emerging sector.
The demonstration project features floaters that capture the natural movement of ocean waves to generate renewable electricity. While still in its pilot phase, the initiative demonstrates the scalability of wave energy and lays the foundation for future commercial expansion along U.S. coastlines.
The launch aligns with California’s ambitious climate agenda and Senate Bill 605, which calls for the development of a comprehensive wave energy roadmap. At the federal level, momentum is also building. Congresswoman Nanette Díaz Barragán recently introduced the Marine Energy Technologies Acceleration Act, a $1 billion initiative to accelerate marine energy nationwide.
“Eco Wave Power made history by deploying its innovative technology into U.S. waters for the very first time,” said Congresswoman Barragán. “This milestone shows incredible potential for wave energy to power communities with clean electricity while creating jobs and protecting our environment.”
Inna Braverman, Founder and CEO of Eco Wave Power, emphasized that the project demonstrates the vital role of policy support in turning innovation into reality. She added that future projects are already in the pipeline in Taiwan, India, and Portugal.
“Wave energy has enormous potential — it is predictable, reliable, and available right on our coastlines,” Braverman said. “Today, we are not just cutting a ribbon. We are opening the door to a new era of clean energy for California and the world.”
You might like this article:NeuroNOS Earns FDA Orphan Drug Designation for Glioblastoma Therapy
